CERPASS : A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

18+Age Over 18

Skin<br/>CancersCancer LocationSkin
Cancers

Systemic therapy | SkinCutaneous Squamous Cell Carcinoma (CSCC)

Trial Overview Read MoreRead more

This phase II trial is assessing the benefits of using a targeted therapy (cemiplimab) in combination with a biological therapy (RP1) to treat patients with advanced or metastatic cutaneous squamous cell carcinoma.
 

This trial is treating patients with Cutaneous Squamous Cell Carcinoma.

This is a systemic therapy.

You may be able to join this trial if:

  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Commercial Sponsor

Replimune Inc.

Summary

Patients eligible to participate in this trial will receive either Cemiplimab alone, or in combination with RP1. Cemiplimab will be intravenously administered every 3 weeks, while RP1 will be administered as an direct injection into the tumour every 3 weeks.

Recruiting Hospitals Read MoreRead more

Alfred Hospital, Medical Oncology
Prahran
Ms Jane Berry
J.Berry@alfred.org.au
03 9076 2629

Monash Health, Medical Oncology
Clayton
Lung Research Study Coordinator
lung.oncresearch@monashhealth.org
0417607146

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Ms Marian Lieschke
marian.lieschke@petermac.org
03 8559 7140

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next